Filters

FRMD2 Antibody, Cy7 Conjugated

FRMD2 Antibody, Cy7 Conjugated size: 0.1ml 350

Price 350
Size 0.1ml
Long name Cy7 Conjugated, FRMD2 Polyclonal Antibody
CategoryConjugated Primary Antibodies
ConjugationCy7
Host OrganismRabbit (Oryctolagus cuniculus)
Target AntigenFRMD2
SpecificityThis is a highly specific antibody against FRMD2
ModificationUnmodified
Modification siteNone
ClonalityPolyclonal
ClonePolyclonal antibody
Concentration1ug per 1ul
SourceKLH conjugated synthetic peptide derived from human FRMD2/FRMPD1
Gene ID number22844
Tested applicationsIF(IHC-P)
Recommended dilutionsIF(IHC-P)(1:50-200)
Crossreactivity Mouse, Rat, Human
Crossreactive species details not every possible cross-reactivity is known, Due to limited amount of testing and knowledge
Antigen backgroundFRMPD1 has been identified as a regulatory binding partner of activator of G-protein signaling 3 (AGS3)
Purification methodThis antibody was purified via Protein A
Storage conditions 50% glycerol and 0, Store refrigerated at 2 to 8 degrees Celcius for up to 1 year, 09% sodium azide, Keep the antibody in an aqueous buffered solution containing 1% BSA
Excitation Emission743nm/767nm
Synonyms KIAA0967 FRMD2
PropertiesC, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies they should be stored frozen at - 24°
ConjugatedThese antibodies are excite for emission at 650 nm and detected at a 676 nm wavelengths
Gene targetFRMD2 Conjugated
Short name Conjugated, FRMD2 Antibody
Technique antibodies against human proteins, antibodies for, antibody Conjugates, Antibody
LabelCy7
Alternative name cyanine 7 coupled, FRMD2 (Antibody to)
Alternative techniqueantibodies
Identity 29159
Gene FRMPD1
Long gene name FERM and PDZ domain containing 1
Locus 9p13, 2
Discovery year 2004-01-05
GenBank acession AB023184
Entrez gene record 22844
Pubmed identfication 10231032
RefSeq identity NM_014907
Classification PDZ domain containing FERM domain containing
Havana BLAST/BLAT OTTHUMG00000019927

Subscribe to our Newsletter